Investors should monitor the upcoming IND filing for Lucid-MS Phase 2 trial and any progress on Unbuzzd's IPO plans, which could unlock significant value. The strong cash runway and reduced liabilities reduce near-term dilution risk, making QNTM a less speculative hold with multiple potential catalysts in 2026.
Price Chart
Executive Summary
Quantum Biopharma reported its 2025 audited financial results, showing improved financial health with $11.3 million in cash and digital assets, reduced operating expenses and payables, and no going concern issues. The company made progress on its MS drug candidate Lucid-MS, completing Phase 1 toxicity studies and advancing toward a Phase 2 trial, while also achieving a peer-reviewed publication for its alcohol metabolism product unbuzzd and securing a Canadian product license for Qlarity. A board member resigned, and Unbuzzd launched a $5M private offering in preparation for a potential IPO.
Key Facts
- Cash on hand and fair market value of digital assets: $11.3 million USD as of filing date
- Operating expenses decreased to $15.3 million in 2025 from $16.1 million in 2024 (-5%)
- Trade and other payables reduced by ~50%, from $4.1 million to $2.0 million
- External R&D fees dropped to $2.8 million from $6.1 million due to completion of Phase 1 trials and Australian R&D tax credits
- Phase 1 oral toxicity studies for Lucid-MS completed with no significant side effects; IND filing planned for H1 2026
- Peer-reviewed publication confirmed unbuzzd accelerates BAC reduction and reduces hangover symptoms
- Health Canada granted product license for Qlarity, allowing Canadian sales
- Unbuzzd launched $5.0 million Regulation D offering and is preparing for IPO; Quantum holds 19.84% stake and will not be diluted
- All hedge fund warrants expired in 2025; special dividend of CVRs distributed October 27, 2025
- Terry Lynch resigned from board effective March 27, 2026
Financial Impact
Cash position of $11.3 million supports operations beyond January 2028; $5.0 million Unbuzzd offering could generate non-dilutive proceeds for Quantum upon monetization. R&D cost savings of $3.3 million year-over-year improved efficiency.
Risk Factors
- Biotech development risk: Lucid-MS is still pre-revenue and must succeed in Phase 2 trials
- Unbuzzd IPO and financing are not guaranteed and depend on market conditions
- Litigation against CIBC and RBC is ongoing with uncertain outcome
- Company relies on future monetization events that are forward-looking and not assured
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-001969 |
| Document: f6k_032626.htm | 0001171843-26-001969 |
| Document: 0001171843-26-001969-index-headers.html | 0001171843-26-001969 |
| Document: 0001171843-26-001969-index.html | 0001171843-26-001969 |
| Document: 0001171843-26-001969.txt | 0001171843-26-001969 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 6-K | $3.11 | awaiting T+20 | — | $2.21 (−28.94%) |
Oct 6, 2026 20d ago | 6-K | $3.09 | awaiting T+20 | — | $2.21 (−28.48%) |
Oct 6, 2026 20d ago | Press Release | $3.09 | awaiting T+20 | — | $2.21 (−28.48%) |
Oct 5, 2026 21d ago | SC 13G/A | $3.27 | awaiting T+20 | — | $2.21 (−32.42%) |
Sep 24, 2026 4w ago | 6-K | $4.00 $2.27 | ▼ −43.25% | ▼ −42.83% | $2.21 (−44.75%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.21 (−40.59%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.21 (−40.59%) |
Sep 15, 2026 5w ago | 6-K | $3.46 $2.89 | ▼ −16.47% | ▼ −19.45% | $2.21 (−36.13%) |
Sep 1, 2026 7w ago | 6-K | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.21 (−28.25%) |
Sep 1, 2026 7w ago | Press Release | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.21 (−28.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers